As the courts increasingly look to efficient resolution of patent disputes through active case management, our clients rely on our strategic advice every step of the way.
Our internationally recognised IP and patent litigation team has acted in many of the most significant intellectual property (IP) disputes in Australia. In addition to the team’s market-leading litigation expertise, many of our lawyers have broader technical qualifications including in chemistry, biotechnology, pharmacology and computer science.
Our team is client-focused, whether providing freedom to operate advice or running multi-jurisdictional litigation. We invest in understanding your business, your market and how your IP drives your competitive advantage and profitability.
Our team is also at the forefront of IP developments and reform, from the matters we lead, submissions we make on policy and our roles on the Law Council of Australia and other international IP bodies.
Our independence allows us to connect our clients with the best IP lawyers around the world, to deliver the best commercial outcomes.
Corrs is representing Tasmanian Alkaloids in relation to various aspects of its technology for genetically-engineered narcotic (opium) poppies. These are processed to prepare narcotic actives that are used in the manufacture of pharmaceutical products for pain relief. In a novel action, our client is seeking preliminary discovery of documents and records from TPI, based on a belief that it may have a claim of patent infringement against TPI, relating to a possible unauthorised early planting of a seed crop to increase volumes of seed for commercial purposes.
Advising on patent infringement, extension and validity litigation against four generic pharmaceutical companies in a dispute relating to an anti-depressant sold as Lexapro. This 14-year-old matter has been running in both the Patent Office with success on liability and damages in the Federal Court.
Advising Merck on patent litigation with Wyeth seeking to revoke patents covering Wyeth’s Prevnar 13 products (vaccines that reduce the incidence of severe ear infections in children, and pneumonia in the elderly). Wyeth has alleged infringement of these patents by the proposed launch of Merck’s own 15-valent vaccine.